Semorinemab failure tempers tau hopes
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Contingent value is back in vogue
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
EHA 2020 – the sickle cell competition hots up
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Tiziana takes a deep breath and targets Covid-19
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
